Skip to main content
Log in

The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and objective

Vildagliptin is a potent, selective, orally active inhibitor of dipeptidylpeptidase-IV being developed for the treatment of type 2 diabetes mellitus. The objective of this study was to assess the absolute oral bioavailability of vildagliptin by comparing the systemic exposure after oral and intravenous administration in healthy volunteers.

Methods

This was an open-label, randomised, two-period, two-treatment, crossover study in 11 healthy volunteers. Subjects received vildagliptin 50mg orally or 25mg as a 30-minute intravenous infusion on two occasions separated by a 72-hour washout period. Vildagliptin concentrations were determined by a specific assay in urine (lower limit of quantification [LLQ] = 5 ng/mL) and serial plasma samples (LLQ = 2 ng/mL) obtained up to 24 hours after dosing. Noncompartmental analysis and population pharmacokinetic modelling were performed.

Results

Both noncompartmental analysis and population pharmacokinetic modelling estimated the absolute oral bioavailability of vildagliptin to be 85%. Renal elimination of unchanged vildagliptin accounted for 33% and 21% of the administered dose 24 hours after intravenous and oral administration, respectively. Renal clearance (13 L/h) was approximately one-third of the total systemic clearance (41 L/h). Two peaks were observed in plasma concentrations at 1 and 3 hours after oral administration in nine of 11 subjects. Modelling based on the population approach identified two absorption sites with lag-times of 0.225 and 2.46 hours. Both absorption rate constants were slower than the elimination rate constant, indicating ‘flip-flop’ kinetics after oral administration. Bodyweight was identified as a factor with an impact on the volume of distribution of the peripheral compartment. Clearance was 24% greater in males (44.6 L/h) than in females (36.1 L/h).

Conclusions

Vildagliptin is rapidly and well absorbed with an estimated absolute bioavailability of 85%. Two possible sites of absorption were identified, and the absorption rates were slower than the elimination rate, indicating a flip-flop phenomenon after oral dosing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Fig. 4
Fig. 5
Table III
Fig. 6
Table IV

Similar content being viewed by others

References

  1. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes. Diabetes 1998 Nov; 47(11): 1663–70

    Article  PubMed  CAS  Google Scholar 

  2. McIntosh CH, Demuth HU, Pospisilik JA, et al. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005 Jun 15; 128(2): 159–65

    Article  PubMed  CAS  Google Scholar 

  3. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005 Apr; 48(4): 616–20

    Article  PubMed  CAS  Google Scholar 

  4. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987 Dec 5; 2(8571): 1300–4

    Article  PubMed  CAS  Google Scholar 

  5. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-l(7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992 May 14; 326(20): 1316–22

    Article  PubMed  CAS  Google Scholar 

  6. Nathan DM, Schreiber E, Fogel H, et al. Insulinotropic action of glucagonlike peptide-I-(7–37) in diabetic and nondiabetic subjects. Diabetes Care 1992 Feb; 15(2): 270–6

    Article  PubMed  CAS  Google Scholar 

  7. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993 Jan; 91(1): 301–7

    Article  PubMed  CAS  Google Scholar 

  8. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 Mar 9; 359(9309): 824–30

    Article  PubMed  CAS  Google Scholar 

  9. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7–36) amide in type I diabetic patients. Diabetes Care 1996 Jun; 19(6): 580–6

    Article  PubMed  CAS  Google Scholar 

  10. D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulinindependent processes: a physiological role of glucagon-like peptide I. Diabetes 1995 Dec; 44(12): 1433–7

    Article  PubMed  Google Scholar 

  11. Prigeon RL, Quddusi S, Paty B, et al. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003 Oct; 285(4): E701–7

    PubMed  CAS  Google Scholar 

  12. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999 Sep; 277 (3 Pt 2): R910–6

    PubMed  CAS  Google Scholar 

  13. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999 May; 276 (5 Pt 2): R1541–4

    PubMed  CAS  Google Scholar 

  14. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002 Nov; 143(11): 4397–408

    Article  PubMed  CAS  Google Scholar 

  15. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003 Jun 19; 46(13): 2774–89

    Article  PubMed  CAS  Google Scholar 

  16. Dardik B, Valentin M, Schwarztkopf C, et al. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys [abstract]. Diabetes 2003; 52 Suppl. 1: A322

    Google Scholar 

  17. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 May; 89(5): 2078–84

    Article  PubMed  CAS  Google Scholar 

  18. Edwards CM. The GLP-1 system as a therapeutic target. Ann Med 2005; 37(5): 314–22

    Article  PubMed  CAS  Google Scholar 

  19. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005 Aug; 90(8): 4888–94

    Article  PubMed  CAS  Google Scholar 

  20. He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interaction between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007; 47: 998–1004

    Article  PubMed  CAS  Google Scholar 

  21. Beal S. NONMEM bug — noninfluential correlated Eta. NONMEM UsersNet Archive 2002 Nov 14 (cited 2006 Nov 13) [online]. Available from URL: http://www.cognigencorp.com/nonmem/nm/99nov142002.html [Accessed 2007 Jul 19]

  22. Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the ‘gastrointestinal bioavailability’ and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985 Jun; 13(3): 289–307

    PubMed  CAS  Google Scholar 

  23. Veng-Pedersen P, Gillespie WR. A note on appropriate constraints on the initial input response when applying deconvolution. J Pharmacokinet Biopharm 1986 Aug; 14(4): 441–7

    PubMed  CAS  Google Scholar 

  24. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton (IL): The Hamilton Press Drug Intelligence Publications, Inc., 1975

  25. Prokop EK, Caride VJ, Winchenbach K, et al. Scintigraphic determination of the effect of metoclopramide and morphine on small intestinal transit time. Am J Physiol Imaging 1988; 3(4): 201–4

    PubMed  CAS  Google Scholar 

  26. Benmair Y, Fischel B, Frei EH, et al. Evaluation of a magnetic method for the measurement of small intestinal transit time. Am J Gastroenterol 1977 Nov; 68(5): 470–5

    PubMed  CAS  Google Scholar 

  27. Scott AM, Kellow JE, Eckersley GM, et al. Cigarette smoking and nicotine delay postprandial mouth-cecum transit time. Dig Dis Sci 1992 Oct; 37(10): 1544–7

    Article  PubMed  CAS  Google Scholar 

  28. Meier R, Beglinger C, Dederding JP, et al. Influence of age, gender, hormonal status and smoking habits on colonic transit time. Neurogastroenterol Motil 1995 Dec; 7(4): 235–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Novartis Pharmaceuticals. Yan-Ling He, Yibin Wang, Joelle Campestrini, Monica Ligueros-Saylan and Dan Howard are employees of Novartis and own stocks in the company. The other authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yan-Ling He.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, YL., Sadler, B.M., Sabo, R. et al. The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers. Clin Pharmacokinet 46, 787–802 (2007). https://doi.org/10.2165/00003088-200746090-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200746090-00006

Keywords

Navigation